Grifols Introduces Recombinant Protein Designed to Overcome Anti-CD38 Antibody Interference

Grifols, an AABB corporate partner, recently introduced sCD38, a new soluble recombinant protein designed to block anti-CD38 antibodies in multiple myeloma patients receiving daratumumab therapy.

Daratumumab is a CD38-directed monoclonal antibody that binds to the CD38 protein on red blood cells. Daratumumab can interfere with blood bank serologic tests and may cause delays in issuing RBC units to patients receiving this therapy.

Through the Grifols sCD38’s novel approach, Grifols aims to provide a more seamless screening, identification and crossmatching process when using the DG Gel system for running pre-transfusion compatibility tests.

The Grifols sCD38 solution has received the CE mark and will be available in certain markets after completion of any additional registration and notification requirements.